| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
BPA and risk assessment
|
Palmer, Kerri
|
|
|
8 |
4 |
p. 269
|
artikel
|
| 2 |
BPA and risk assessment
|
Dupuis, Antoine
|
|
|
8 |
4 |
p. 270-271
|
artikel
|
| 3 |
BPA and risk assessment
|
Calafat, Antonia M
|
|
|
8 |
4 |
p. 269-270
|
artikel
|
| 4 |
BPA and risk assessment – Authors' reply
|
Hunt, Patricia A
|
|
|
8 |
4 |
p. 271-272
|
artikel
|
| 5 |
Can a low-cost, highly effective approach to diabetes find sufficient funding in the USA?
|
Nierengarten, Mary Beth
|
|
|
8 |
4 |
p. 276
|
artikel
|
| 6 |
Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression
|
van Sloten, Thomas T
|
|
|
8 |
4 |
p. 325-336
|
artikel
|
| 7 |
Denosumab salvage therapy in a patient with a locally advanced and refractory sellar giant cell tumour of bone
|
Marques, Pedro
|
|
|
8 |
4 |
p. 348
|
artikel
|
| 8 |
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
|
Tofte, Nete
|
|
|
8 |
4 |
p. 301-312
|
artikel
|
| 9 |
Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
|
Johansen, Nicklas J
|
|
|
8 |
4 |
p. 313-324
|
artikel
|
| 10 |
El susto and the Mexican sugar tax
|
Burki, Talha Khan
|
|
|
8 |
4 |
p. 277
|
artikel
|
| 11 |
GLP-1 receptor agonists in type 1 diabetes: a MAG1C bullet?
|
Nauck, Michael A
|
|
|
8 |
4 |
p. 262-264
|
artikel
|
| 12 |
Glycaemic status during pregnancy and longitudinal measures of fetal growth in a multi-racial US population: a prospective cohort study
|
Li, Mengying
|
|
|
8 |
4 |
p. 292-300
|
artikel
|
| 13 |
Growing fat in utero: timing is everything
|
van Poppel, Mireille NM
|
|
|
8 |
4 |
p. 259-260
|
artikel
|
| 14 |
Metabolic surgery: one size fits all?
|
Novik, Bengt
|
|
|
8 |
4 |
p. 272-273
|
artikel
|
| 15 |
Metabolic surgery: one size fits all? – Authors' reply
|
Hjelmesæth, Jøran
|
|
|
8 |
4 |
p. 273
|
artikel
|
| 16 |
Metformin: the white knight fighting corticosteroid side-effects
|
Reincke, Martin
|
|
|
8 |
4 |
p. 258-259
|
artikel
|
| 17 |
Metformin to reduce metabolic complications and inflammation in patients on systemic glucocorticoid therapy: a randomised, double-blind, placebo-controlled, proof-of-concept, phase 2 trial
|
Pernicova, Ida
|
|
|
8 |
4 |
p. 278-291
|
artikel
|
| 18 |
NCD threat: falling on deaf ears
|
The Lancet Diabetes & Endocrinology,
|
|
|
8 |
4 |
p. 257
|
artikel
|
| 19 |
NICE guidance on sotagliflozin for type 1 diabetes
|
Adler, Amanda I
|
|
|
8 |
4 |
p. 274-275
|
artikel
|
| 20 |
Pyrethroid exposure: not so harmless after all
|
Demeneix, Barbara
|
|
|
8 |
4 |
p. 266-268
|
artikel
|
| 21 |
Screening for diabetic retinopathy: new perspectives and challenges
|
Vujosevic, Stela
|
|
|
8 |
4 |
p. 337-347
|
artikel
|
| 22 |
Use of urinary proteomics in diagnosis and monitoring of diabetic kidney disease
|
Nicholas, Susanne B
|
|
|
8 |
4 |
p. 261-262
|
artikel
|
| 23 |
Variation in the classification of hyperglycaemia in pregnancy and its implication
|
Gupta, Yashdeep
|
|
|
8 |
4 |
p. 264-266
|
artikel
|
Tijdschrift beschrijving